ClinicalTrials.gg
CompletedNCT07913035Updated Nov 3, 2026

Post-extraction Bleeding in Older Adults on Uninterrupted Antiplatelet Therapy

An observational study in Tooth Extraction, Postoperative Hemorrhage and Platelet Aggregation Inhibitors, sponsored by University of Medicine and Pharmacy at Ho Chi Minh City. Completed at 1 site in Vietnam. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by University of Medicine and Pharmacy at Ho Chi Minh City · Observational

Updated Nov 3, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
210
Ages
40 Years and older
Sex
All
01

Study summary

This prospective, assessor-blinded, controlled observational study compares bleeding after simple tooth extraction between adults aged 40 years or older who continue their antiplatelet therapy (aspirin, clopidogrel or dual antiplatelet therapy) without interruption and controls taking no drug that affects haemostasis. Socket bleeding is graded at 15, 30, 45 and 60 minutes within a stepwise local haemostatic protocol, and recurrent bleeding is monitored by telephone for 72 hours. The study also explores demographic, clinical and pharmacological factors associated with prolonged and recurrent bleeding among patients on antiplatelet therapy.

Read the detailed description

Patients receiving long-term antiplatelet therapy for cardiovascular or cerebrovascular disease increasingly require dental extractions. Guidelines recommend continuing antiplatelet therapy for low-bleeding-risk procedures, but prospective data from older Southeast Asian patients, among whom clopidogrel is widely prescribed, are lacking.

Consecutive eligible patients on uninterrupted antiplatelet therapy and controls frequency-matched for sex and tooth type are enrolled at the Department of Odonto-Stomatology, Ba Ria General Hospital, Vietnam. Before extraction, patients on antiplatelet therapy undergo a complete blood count, PT, INR and aPTT, and a cardiologist confirms that therapy should be continued. All simple extractions of one to three teeth are performed by one experienced oral surgeon under 2% lidocaine with 1:100,000 epinephrine (maximum two cartridges).

A blinded assessor grades socket bleeding as none, mild or severe at 15 (T1), 30 (T2), 45 (T3) and 60 (T4) minutes. Bleeding sockets are managed stepwise: gauze pressure until T2, a gelatin sponge at T2, and topical tranexamic acid with sutures at T3; persistent bleeding at T4 would prompt hospital observation. Recurrent bleeding after discharge is assessed by structured telephone interviews at 24, 48 and 72 hours. Groups are compared with Fisher's exact and Mann-Whitney U tests, and factors associated with prolonged and recurrent bleeding in the antiplatelet group are explored with Firth-penalised logistic regression.

02

Conditions studied

  • Tooth Extraction
  • Postoperative Hemorrhage
  • Platelet Aggregation Inhibitors

Keywords

  • antiplatelet therapy
  • dual antiplatelet therapy
  • clopidogrel
  • aspirin
  • post-extraction bleeding
  • hemostasis
03

In context

Postoperative Hemorrhage

135 studies on the registry are indexed under Postoperative Hemorrhage; 31 are open to participants now.

This study's enrollment of 210 is above the median of 100 across 29 observational studies indexed under Postoperative Hemorrhage.

Browse Postoperative Hemorrhage studies →

Lead sponsor

University of Medicine and Pharmacy at Ho Chi Minh City is the lead sponsor of 127 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults aged 40 years or older with an indication for simple extraction of one to three teeth at the Department of Odonto-Stomatology, Ba Ria General Hospital, Vietnam: consecutive patients on uninterrupted antiplatelet therapy and controls taking no drug that affects haemostasis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40 years or older
  • Indication for simple (non-surgical) extraction of one to three teeth
  • I or II
  • APT group: taking aspirin, clopidogrel or dual antiplatelet therapy without interruption during the 7 days before extraction
  • Control group: not taking any drug affecting haemostasis (vitamin K antagonists, direct oral anticoagulants, antiplatelet agents or non-steroidal anti-inflammatory drugs)
  • Written

Exclusion criteria

Exclusion Criteria:

  • Self-discontinuation of antiplatelet therapy without medical advice
  • Thrombocytopenia or other disorders
  • Inherited or acquired coagulopathies (e.g., haemophilia, von Willebrand disease, systemic lupus erythematosus)
  • Current use of vitamin K antagonists or direct oral anticoagulants
  • Severe hepatic disease or renal failure requiring dialysis
  • Ongoing radiotherapy or chemotherapy
  • Acute infection at the extraction site
  • Known allergy to any drug or material used in the study
  • Inability to cooperate
  • Conversion to surgical extraction or incomplete telephone follow-up (withdrawn from analysis)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
210 participants (actual)
Patient registry
No

Groups and cohorts

  • Antiplatelet therapy (APT) group

    Adults aged 40 years or older taking aspirin, clopidogrel or dual antiplatelet therapy without interruption during the 7 days before simple extraction of one to three teeth.

    Drug: Antiplatelet therapy (uninterrupted) · Procedure: Simple tooth extraction with stepwise local haemostatic protocol

  • Control group

    Adults aged 40 years or older taking no drug that affects haemostasis, recruited during the same period and frequency-matched to the APT group for sex and tooth type, undergoing simple extraction of one to three teeth.

    Procedure: Simple tooth extraction with stepwise local haemostatic protocol

Interventions

  • Aspirin 81 mg/day, clopidogrel 75 mg/day, or aspirin 100 mg plus clopidogrel 75 mg/day (dual antiplatelet therapy), continued without interruption as prescribed by the patient's physician. Antiplatelet therapy is not assigned by the investigators.

    Also known as: Aspirin, Clopidogrel

  • ProcedureSimple tooth extraction with stepwise local haemostatic protocol

    Non-surgical extraction of one to three teeth by one experienced oral surgeon under 2% lidocaine with 1:100,000 epinephrine (maximum two cartridges), followed by gauze pressure; a gelatin sponge is placed at 30 minutes and topical tranexamic acid irrigation with sutures is applied at 45 minutes when bleeding persists.

06

What researchers measure

Primary outcomes

  1. Proportion of Sockets With Residual Bleeding at 15 Minutes

    Socket bleeding is graded by a blinded assessor after gauze removal as none (no visible bleeding), mild (oozing without continuous flow) or severe (immediate, continuous flow). Residual bleeding is defined as mild or severe bleeding.

    Time frame: 15 minutes after tooth extraction

  2. Proportion of Sockets With Residual Bleeding at 30 Minutes

    Same three-level grading (none, mild, severe) after continued gauze pressure. Residual bleeding is defined as mild or severe bleeding.

    Time frame: 30 minutes after tooth extraction

Secondary outcomes

  1. Proportion of Sockets With Residual Bleeding at 45 and 60 Minutes

    Same three-level grading after gelatin sponge placement (45 minutes) and after topical tranexamic acid irrigation with sutures (60 minutes).

    Time frame: 45 and 60 minutes after tooth extraction

  2. Time to Haemostasis

    Time from tooth delivery to the first assessment at which no bleeding is observed, in minutes.

    Time frame: Up to 60 minutes after tooth extraction

  3. Most Advanced Local Haemostatic Measure Required

    Proportion of visits managed with gauze pressure only, a gelatin sponge, or topical tranexamic acid with sutures.

    Time frame: Up to 60 minutes after tooth extraction

  4. Recurrent Bleeding After Discharge

    Any bleeding reported after discharge once haemostasis had been achieved, assessed by structured telephone interviews at 24, 48 and 72 hours; timing and management are recorded.

    Time frame: Up to 72 hours after tooth extraction

  5. Factors Associated With Prolonged and Recurrent Bleeding in the Antiplatelet Therapy Group

    Odds ratios from Firth-penalised logistic regression for age, sex, number of teeth extracted, extraction time, platelet count and antiplatelet regimen.

    Time frame: 30 minutes and 72 hours after tooth extraction

07

Study locations

1 site
  • Ba Ria General Hospital
    Bà Ria, Ho Chi Minh City, Vietnam
08

References and documents

Individual participant data

Plan to share: Undecided — De-identified data are available from the corresponding author on reasonable request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Aug 2025, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2026
First posted
Nov 3, 2026
StartActual
Sep 1, 2024
Primary completionActual
Aug 30, 2025
CompletionActual
Aug 30, 2025
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07913035
Collaborators
Ba Ria General Hospital
Responsible party
Son Hoang Le (Principal Investigator, University of Medicine and Pharmacy at Ho Chi Minh City) — Principal investigator
First posted
Nov 3, 2026
Start date
Sep 1, 2024
Primary completion
Aug 30, 2025
Completion
Aug 30, 2025
Last update
Nov 3, 2026

Study contacts

Son H Le, PhD
principal investigator · University of Medicine and Pharmacy at Ho Chi Minh City

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion